The Chinese State Administration for Market Regulation fines three domestic pharmaceutical companies for abuse of dominance in the sale of injectable pharmaceutical ingredient (Kanghui / Puyunhui / Taiyangshen)

On 9 April 2020, China's State Administration for Market Regulation (SAMR) fined three domestic pharmaceutical companies Shandong Kanghui Medicine Company Limited ("Kanghui"), Weifang Puyunhui Pharmaceutical Company Limited ("Puyunhui") and Weifang Taiyangshen Company Limited Pharmaceutical ("Taiyangshen"), a total of RMB 325.5 million (approx. USD 46.2 million) for abuse of dominance (i.e., excessive pricing and imposing unfair trading conditions) in the sale of injectable calcium gluconate active pharmaceutical ingredient (API). This is so far the largest antitrust penalty imposed in the China pharmaceutical sector. The penalty sets multiple records for Chinese antitrust enforcement in terms of setting the ceiling penalty for both antitrust violations and obstructing antitrust

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • FenXun Partners (Beijing)
  • Baker McKenzie (Beijing)
  • Baker McKenzie (Beijing)
  • Baker McKenzie (Hong Kong)
  • Baker McKenzie (Hong Kong)

Quotation

Zhi Bao, Laura Liu, Wenting Ge, Stephen Crosswell, Thomas Jenkins, The Chinese State Administration for Market Regulation fines three domestic pharmaceutical companies for abuse of dominance in the sale of injectable pharmaceutical ingredient (Kanghui / Puyunhui / Taiyangshen), 9 April 2020, e-Competitions May 2020 - II, Art. N° 94832

Visites 77

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues